REMOXY(R) NDA Filing Accepted by FDA and Priority Revi... (prnews?PageQuote&TickerKG onClick var s...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted

Date:8/12/2008

prnews?Page=Quote&Ticker=KG" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >KG). REMOXY, an investigational drug, is a unique, abuse-resistant, controlled release oxycodone for moderate-to-severe chronic pain.

About ORADUR(TM) Technology

ORADUR is a proprietary technology designed to transform short-acting oral capsule dosage forms into sustained release oral products, with the added benefit of being less prone to abuse (e.g. by crushing or water extraction) than other controlled release dosage forms on the market today.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary (oral, transdermal and injectable depot) delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: ORADUR(TM), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding REMOXY, its attributes, the timing of FDA review of the NDA and its potential to be the first oxycodone on the market that deters common methods of abuse are forward-looking statements involving risks and uncertainties that can cause actual results to differ m
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
2. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
3. Embryo Viability Studies Support Utility of Novel, Metabolomic Profiling Technology
4. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
5. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
8. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens

Post Your Comments:

[0] Helix BioPharma Corp. Announces Fiscal Q1 2010 Results [0] Roper Industries Completes the Acquisition of Verathon, Inc.[0] Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities

Other Medicine Technology:For Iraq Veterans, Headaches Continue After Traumatic Brain Injury 2

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)

Breaking Medicine News(10 mins):Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 2 Health News:IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care 3 Health News:Sticks and stones break bones, but this UH study may prevent it 2 Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2 Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3 Health News:Webcast Alert: MicroRNA: The Year in Review 2

[0] IBM Chosen to Build System for Electronic Health Records in Manitoba for Improved Patient Care [0] Sticks and stones break bones, but this UH study may prevent it [0] Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries [0] Webcast Alert: MicroRNA: The Year in Review [0] Oxycodone Linked to Rise in Opioid-Related Deaths

Global Med Technologies(R) to Present at Rodman & Renshaw 9th Annual Healthcare Conference Amira Pharmaceuticals Appoints First Vice President of Development Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track Study Shows Antibiotic Harms ALS Patients Exclusive American Council on Exercise (ACE) Research Study Proves Functional Fitness Really Works Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint

Medicine Products:

Baerveldt Glaucoma Implant Easyfield Octopus 101 Octopus 301

REMOXY(R) NDA Filing Accepted by FDA and Priority Revi...(prnews?PageQuote&TickerKG onClick var s...),Health